| abstract |
FIELD: medicine; pharmaceuticals. n SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and provides methods for treating acute myeloid leukemia (AML) in a patient aged over 65 using a medicament and the medicament itself, comprising a suspension of erythrocytes with an asparaginase encapsulated therein as an active component, where one dose of the suspension comprises 50 to 500 IU of encapsulated asparaginase per kg of body weight. In these methods of treating AML, one or more doses of the suspension are administered to the patient during the induction phase or during the treatment phase. n EFFECT: group of inventions makes it possible to administer an effective dose of L-asparaginase to patients aged over 65 without toxic effects, by encapsulating L-asparaginase in an erythrocyte suspension. n 23 cl, 2 dwg, 2 tbl, 10 ex |